Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: A single center cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 28 01 2023
accepted: 19 07 2023
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: epublish

Résumé

The Delta variant has led to a surge in COVID-19 cases in Libya, making it crucial to investigate the impact of vaccination on mortality rates among hospitalized patients and the critically ill. This study aimed to explore the risk factors for COVID-19 mortality and the mortality rates among unvaccinated and vaccinated adults during the Delta wave who were admitted to a single COVID-19 care center in Tripoli, Libya. The study involved two independent cohorts (n = 341). One cohort was collected retrospectively from May 2021-August 2021 and the second cohort was prospectively collected from August 2021-October 2021. Most of the patients in the study became ill during the Delta wave. The two cohorts were merged and analysed as one group. Most patients were male (60.5%) and 53.3% were >60 years old. The vast majority of patients did not have a previous COVID-19 infection (98.9%) and were unvaccinated (90.3%). Among vaccinated patients, 30 had received one dose of vaccine and only 3 had received two doses. Among patients who received one dose, 58.1% (18/31) died and 41.9% (13/31) survived. Most patients (72.2%) had a pre-existing medical condition. A multivariable prediction model showed that age >60 years was significantly associated with death (odds ratio = 2.328, CI 1.5-3.7, p-value = <0.0001). Our results indicate that previous infection or full vaccination against COVID-19 significantly reduces hospitalization and death. However, a single vaccine dose may not be adequate, especially for older individuals and those with underlying medical conditions. High-risk older patients with comorbidities should be fully vaccinated and offered up to date bivalent COVID-19 booster doses.

Identifiants

pubmed: 37540662
doi: 10.1371/journal.pone.0289490
pii: PONE-D-23-02510
pmc: PMC10403102
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0289490

Informations de copyright

Copyright: © 2023 Alhudiri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Vaccines (Basel). 2022 Nov 24;10(12):
pubmed: 36560411
J Epidemiol Glob Health. 2021 Mar;11(1):98-104
pubmed: 33095982
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
BMC Infect Dis. 2022 Aug 22;22(1):702
pubmed: 35996076
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):206-211
pubmed: 35143464
Med J Aust. 2022 Oct 3;217(7):352-360
pubmed: 35686307
JAMA Netw Open. 2020 Jun 1;3(6):e2012270
pubmed: 32543702
Libyan J Med. 2022 Dec;17(1):2121252
pubmed: 36062935
Glob Epidemiol. 2022 Dec;4:100071
pubmed: 35018339
PLoS One. 2021 Mar 25;16(3):e0249038
pubmed: 33765049
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
PLoS One. 2022 Mar 31;17(3):e0265529
pubmed: 35358238
Crit Care Med. 2022 Feb 1;50(2):245-255
pubmed: 34259667
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Libyan J Med. 2021 Dec;16(1):2001210
pubmed: 34757863
Travel Med Infect Dis. 2020 Sep - Oct;37:101705
pubmed: 32360409
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Med J Armed Forces India. 2021 Jul;77:S278-S282
pubmed: 34334894
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Adv Respir Med. 2021;89(2):135-144
pubmed: 33966261
J Med Virol. 2020 Nov;92(11):2465-2472
pubmed: 32525568
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466

Auteurs

Inas Alhudiri (I)

Libyan Biotechnology Research Center, Tripoli, Libya.

Zakarya Abusrewil (Z)

Department of Forensic and toxicology, Faculty of Medicine, University of Tripoli, Tripoli, Libya.
National Migration Health, International Organization for Migration, Tripoli, Libya.

Omran Dakhil (O)

Souq Thullatha Isolation Center, Tripoli, Libya.

Mosab Ali Zwaik (MA)

Souq Thullatha Isolation Center, Tripoli, Libya.

Mohammed Ammar Awn (MA)

Souq Thullatha Isolation Center, Tripoli, Libya.

Mwada Jallul (M)

Department of Forensic and toxicology, Faculty of Medicine, University of Tripoli, Tripoli, Libya.

Aimen Ibrahim Ahmed (AI)

National Migration Health, International Organization for Migration, Tripoli, Libya.

Rasha Abugrara (R)

National Migration Health, International Organization for Migration, Tripoli, Libya.

Adam Elzagheid (A)

Libyan Biotechnology Research Center, Tripoli, Libya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH